1. Iridex published a study on laser treatments for glaucoma. 2. The study compares CW-TSCPC and MicroPulse TLT thermal effects. 3. MicroPulse TLT shows better heat distribution and safety features. 4. Innovations may enhance glaucoma treatment effectiveness and outcomes. 5. CEO emphasizes commitment to evidence-based innovation in glaucoma care.
FAQ
Why Bullish?
The research enhances Iridex's product offerings, potentially increasing demand. Historical innovations have led to price appreciation in similar biotech firms.
How important is it?
The research directly relates to Iridex’s innovative products, indicating strong future market position.
Why Long Term?
The findings could lead to improved product trust and adoption over time, influencing market perception.
Iridex Releases Key Study on MicroPulse® Technology for Glaucoma Treatment
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) – Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical solutions for glaucoma and retinal diseases, has announced the publication of a pivotal study in Translational Vision Science & Technology. This study examines the thermal dynamics involved in transscleral laser treatments for glaucoma and employs advanced modeling techniques to provide critical insights.
An In-Depth Look at the Study
The research, led by Dr. Tomas M. Grippo of the Grippo Glaucoma & Cataract Center in Buenos Aires, Argentina, is the first to conduct a quantitative comparison between the thermal effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and the MicroPulse® technology (MicroPulse TLT) utilizing Iridex’s Cyclo G6® Laser, G-Probe®, and MicroPulse P3® delivery devices.
Leveraging advanced Monte Carlo computer simulations, the study modeled tissue heating within the ciliary body, revealing significant differences in thermal behavior:
- CW-TSCPC induced a 2 mm-wide zone of heating exceeding 100°C for approximately 2.2 seconds.
- MicroPulse TLT produced a smaller thermal zone of 0.6-1.2 mm with peak temperatures remaining below 100°C.
- MicroPulse TLT demonstrated a more even distribution of heat compared to CW-TSCPC.
Expert Insights and Implications
Dr. Grippo emphasized the significance of this research, stating, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action, we reinterpret existing clinical evidence from a fresh perspective.” This approach aims to enhance the understanding of these techniques and refine treatment procedures for better patient outcomes.
The study concludes that both procedures share a thermal continuum, suggesting that with further optimization, they could serve distinct roles in treating refractory glaucoma and in earlier intervention strategies.
Company Commitment to Innovation
Patrick Mercer, CEO of Iridex Corporation, remarked, “Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care. By deepening our scientific understanding of these transscleral laser approaches, we can continue to improve treatment optimization and safety, creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in glaucoma management.”
This research not only solidifies Iridex’s position as a frontrunner in the ophthalmic laser technology market but also enhances the clinical framework for their innovative products designed to treat glaucoma effectively.
About Iridex Corporation
Iridex Corporation is a worldwide leader in designing, manufacturing, and marketing advanced laser-based medical systems. Their products, including the proprietary MicroPulse® technology, minimize tissue damage while delivering effective treatments for conditions like glaucoma and diabetic macular edema (DME). Iridex’s offerings are available in over 100 countries through a global network of distributors and direct sales in the United States.
For further details, visit the Iridex website at www.iridex.com.
Contact Information
Investor Relations:
Philip Taylor
Gilmartin Group
investors@iridex.com
Media Contact:
Joan Stauffer
jstauffer@iridex.com